Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality.
Chloroplast genetic engineering offers several advantages, including high levels of transgene expression, transgene containment via maternal inheritance, and multi-gene expression in a single transformation event. Oral delivery is facilitated by hyperexpression of vaccine antigens against cholera, tetanus, anthrax, plague, or canine parvovirus (4%-31% of total soluble protein, TSP) in transgenic chloroplasts (leaves) or non-green plastids (carrots, tomato) as well as the availability of antibiotic free selectable markers or the ability to excise selectable marker genes. Hyperexpression of several therapeutic proteins, including human serum albumin (11.1% TSP), somatotropin (7% TSP), interferon-alpha (19% TSP), interferon-gamma (6% TSP), and antimicrobial peptide (21.5% TSP), facilitates efficient and economic purification. Also, the presence of chaperones and enzymes in chloroplasts facilitates assembly of complex multisubunit proteins and correct folding of human blood proteins with proper disulfide bonds. Functionality of chloroplast-derived vaccine antigens and therapeutic proteins has been demonstrated by several assays, including the macrophage lysis assay, GM1-ganglioside binding assay, protection of HeLA cells or human lung carcinoma cells against encephalomyocarditis virus, systemic immune response, protection against pathogen challenge, and growth or inhibition of cell cultures. Purification of human proinsulin has been achieved using novel purification strategies (inverse temperature transition property) that do not require expensive column chromatography techniques. Thus, transgenic chloroplasts are ideal bio-reactors for production of functional human and animal therapeutic proteins in an environmentally friendly manner.
Chebolu
S
S
Department of Molecular Biology & Microbiology, University of Central Florida, 336 Biomolecular Science (Bldg # 20), Orlando, FL 32816-2360, USA.
Daniell
H
H
D000818:Animals; D000942:Antigens, Bacterial / Q000096:biosynthesis* / Q000276:immunology; D000956:Antigens, Viral / Q000096:biosynthesis* / Q000276:immunology*; D002736:Chloroplasts / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D030821:Plants, Genetically Modified; D017510:Protein Folding; D011994:Recombinant Proteins / Q000378:metabolism* / Q000627:therapeutic use*
D000942:Antigens, Bacterial; D000956:Antigens, Viral; D011994:Recombinant Proteins